Menu
FDA DECISION ·
Tecentriq / Tecentriq Hybreza
atezolizumab or atezolizumab and hyaluronidase-tqjs · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adjuvant monotherapy for adults with muscle-invasive bladder cancer after cystectomy and circulating tumor DNA molecular residual disease (ctDNA MRD) detected by an FDA-authorized test.
LAMPGEN ANALYSIS
Why it matters
This approval makes a post-surgery molecular signal actionable in bladder cancer. The randomized IMvigor011 population came from serial testing after cystectomy.
What research teams should watch
Define who orders and tracks serial MRD tests, who receives positive results and how referrals are closed. The operational question is whether patients can complete testing and start therapy in time.
Clinical operations takeaway
Assign an owner to each handoff from the scheduled draw and lab receipt to the returned result and documented follow-up. Review missed draws, late reports, and unresolved actions during site and study reviews.
Plan biomarker screening and specimen workflowsRelated study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Perioperative muscle-invasive bladder cancerPRIMARY RECORDS